Parallel Review Could Deter NCD, Medicare Exec Says; Provenge A Case In Point?
Executive Summary
Overlapping FDA product approval and Medicare coverage reviews could help biopharmaceutical firms avoid a later Medicare national coverage determination for a new therapy, CMS Coverage and Analysis Group Director Louis Jacques suggested during a webinar sponsored by Avalere Health Sept. 30.
You may also be interested in...
FDA/CMS Parallel Review: Firms Lack Incentive To Participate, Lawyers Say
As drug industry advisors scrutinize FDA’s and CMS’ recent proposal to institute voluntary parallel reviews of new medical products, some are seeing little reason for manufacturers to subject their products to parallel review.
FDA/CMS Parallel Review: Firms Lack Incentive To Participate, Lawyers Say
As drug industry advisors scrutinize FDA’s and CMS’ recent proposal to institute voluntary parallel reviews of new medical products, some are seeing little reason for manufacturers to subject their products to parallel review.
Provenge Off-Label Use Is Key CMS Concern In NCA, Dendreon Says
In its ongoing national coverage analysis of Dendreon's Provenge (sipuleucel-T), the Centers for Medicare and Medicaid Services is taking a close look at Medicare coverage for off-label use of the novel prostate cancer vaccine, according to the company